The logo of pharmaceutical institution Novo Nordisk is displayed successful beforehand of its offices successful Bagsvaerd, connected the outskirts of Copenhagen, Denmark, Nov. 24, 2025.
Tom Little | Reuters
The U.S. Food and Drug Administration connected Monday approved the first-ever GLP-1 pill for obesity from Novo Nordisk, a landmark determination that wellness experts accidental could perchance unfastened up attraction entree to much patients.
The support besides gives Novo Nordisk a caput commencement implicit main rival Eli Lilly, which is presently the ascendant subordinate successful the marketplace and is racing to motorboat its ain obesity pill. Pills are the adjacent battleground for the 2 drugmakers, which established the booming GLP-1 abstraction that immoderate analysts accidental could beryllium worthy astir $100 cardinal by the 2030s.
Wall Street thinks there's plentifulness of country for pills successful the market, with Goldman Sachs expert saying successful August that pills could seizure a 24% stock — oregon astir $22 cardinal — of the 2030 planetary value nonaccomplishment cause market.
This is breaking news. Please refresh for updates.
English (US) ·